Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

医学内科学移植临床终点阿糖胞苷人口米托蒽醌诱导化疗造血干细胞移植外科化疗随机对照试验环境卫生

作者

Matthias Stelljes,Jan Moritz Middeke,Gesine Bug,Eva‐Maria Wagner‐Drouet,Lutz Müller,Christoph Schmid,Stefan W. Krause,Wolfgang Bethge,Edgar Jost,Uwe Platzbecker,Stefan Klein,Jörg Schubert,Judith Niederland,Martin Kaufmann,Kerstin Schäfer‐Eckart,Markus Schaich,Henning Baldauf,Friedrich Stölzel,Cathleen Petzold,Christoph Röllig,Nael Alakel,Björn Steffen,Beate Hauptrock,Christoph Schliemann,Katja Sockel,Fabian Lang,Oliver Kriege,Judith Schaffrath,Christian Reicherts,Wolfgang E. Berdel,Hubert Serve,Gerhard Ehninger,Alexander H. Schmidt,Martin Bornhäuser,Jan‐Henrik Mikesch,Johannes Schetelig,Nael Alakel,Jörn C. Albring,Wolfgang E. Berdel,Wolfgang Bethge,Martin Bornhäuser,Gesine Bug,Christoph Buhl,Simon Call,Martina Crysandt,Katharina Egger‐Heidrich,Eva Eßeling,Christoph Faul,Georg‐Nikolaus Franke,Julia-Annabell Georgi,Julia Glück-Wolf,Christoph Groth,Beate Hauptrock,Daniela Heidenreich,Snjezana Janjetovic,Edgar Jost,Martin Kaufmann,Thomas Kindler,Stefan Klein,Stefan W. Krause,Sebastian Kreil,Theresa Kretschmann,Désirée Kunadt,Fabian Lang,Georg Lenz,Sonja Martin,Julia Marx,Jan-Moritz Middeke,Jan‐Henrik Mikesch,Lutz Müller,Nadine Müller,Judith Niederland,Stefani Parmentier,Kathrin Petzold,Uwe Platzbecker,Andreas Rank,Christian Reicherts,Christoph Röllig,Wolf Rösler,Kerstin Schäfer‐Eckart,Judith Schaffrath,Markus Schaich,Johannes Schetelig,Christoph Schliemann,Christoph Schmid,Dominik Schneidawind,Jörg Schubert,Hubert Serve,Katja Sockel,Björn Steffen,Matthias Stelljes,Raphael Teipel,Malte von Bonin,Eva Wagner-Drouet,Maxi Wass,Knut Wendelin

出处

期刊：The Lancet Haematology [Elsevier]
日期：2024-04-04 卷期号：11 (5): e324-e335 被引量：8

链接

thelancet.com uni-augsburg.de uni-augsburg.de nih.govdoi.org

标识

DOI：10.1016/s2352-3026(24)00065-6

摘要

Whether high-dose cytarabine-based salvage chemotherapy, administered to induce complete remission in patients with poor responsive or relapsed acute myeloid leukaemia scheduled for allogeneic haematopoietic stem-cell transplantation (HSCT) after intensive conditioning confers a survival advantage, is unclear.

求助该文献

Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

今日热心研友